ASH Expert Roundtable: DLBCL

Latest ASH Expert Roundtable: DLBCL News

Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T

A phase Ib/II study demonstrated that mosunetuzumab (Lunsumio) plus polatuzumab vedotin (Polivy)

Derick Alison Derick Alison

Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients

Durable responses were seen when axicabtagene ciloleucel (axi-cel; Yescarta) was administered as

Derick Alison Derick Alison

Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL

Initial treatment with lenalidomide (Revlimid), tafasitamab (Monjuvi), rituximab, and acalabrutinib (Calquence) led

Derick Alison Derick Alison

Positive Results for Odronextamab in Relapsed/Refractory DLBCL

In a pivotal phase II study, the investigational bispecific antibody odronextamab demonstrated

Derick Alison Derick Alison
adbanner